title: [Serious loss of vision in bilateral anterior ischemic optic neuropathy caused by interferon].
abstract: BACKGROUND
  We treated a patient with anterior ischemic optic neuropathy caused by peginterferon.
  
  
  METHODS
  Upon medical examination of the eyes before starting interferon therapy for chronic hepatitis C at Saiseikai Izuo hospital, a 64-year-old man showed corrected visual acuity of 0.9 in the right eye and 1.0 in the left. No abnormality was visible in either eye except for mild cataracts. Six weeks after combination therapy with peginterferon alpha-2b and ribavirin was started, corrected visual acuity was found to have decreased in the right eye, and swelling of the optic nervehead in both eyes was evident. Bilateral anterior ischemic optic neuropathy caused by interferon therapy was diagnosed. Combination therapy with peginterferon alpha-2 b and ribavirin was discontinued, and administration of prednisolone was started at a dose of 60 mg. However, visual acuity declined in both eyes and the visual field defects worsend. At the most recent examination, visual acuity was 1.0 in the right eye and 0.01 in the left. The visual field included only the temporal periphery in the left eye, and part of the central and upper temporal periphery in the right.
  
  
  CONCLUSIONS
  Since the outcome of visual acuity and visual fields in anterior ischemic optic neuropathy caused by interferon can be poor, an effective therapy for this complication needs to be developed.
authors.affiliation: Department of Ophthalmology, Osaka Saiseikai Izuo Hospital, Osaka, Japan. kkiuchi1@yahoo.co.jp
authors.forename: Katsuji
authors.initials: K
authors.lastname: Kiuchi
authors.forename: Chiemi
authors.initials: C
authors.lastname: Kitagawa
authors.forename: Miki
authors.initials: M
authors.lastname: Miyashiro
mesh_terms: D004359:Drug Therapy, Combination; D019698:Hepatitis C, Chronic / Q000188:drug therapy; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D018917:Optic Neuropathy, Ischemic / Q000139:chemically induced* / Q000188:drug therapy / Q000503:physiopathology; D011092:Polyethylene Glycols; D011239:Prednisolone / Q000008:administration & dosage; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage; D014792:Visual Acuity; D014794:Visual Fields
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; D011239:Prednisolone; C417083:peginterferon alfa-2b